S2721 Did the Drug Do It? A Hepatic Conundrum: Vedolizumab-Related Liver Injury

Sundar, Preeyanka; Kosuru, Suma Harsha; Hillam, Matthew; Ancello, Sara

doi:10.14309/01.ajg.0000784416.58649.28

Am J Gastroenterol

2021

DOI: 10.14309/01.ajg.0000784416.58649.28

|View full text |Cite

S2721 Did the Drug Do It? A Hepatic Conundrum: Vedolizumab-Related Liver Injury

Preeyanka Sundar

Suma Harsha Kosuru²,

Matthew Hillam

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mesalazine/vedolizumab

2021

Reactions Weekly

View full text Add to dashboard Cite

Treatment failure and drug induced liver injury: case reportA 36-year-old woman exhibited treatment failure with mesalazine for Crohn's disease. Additionally, she also developed drug induced liver injury during treatment with vedolizumab for Crohn's disease [routes and dosages not stated].The woman, who had Crohn's disease and had been receiving mesalazine [mesalamine], presented with abdominal pain and fever. Laboratory test were determined and liver biopsy was suggestive of concurrent herpes simplex virus (HSV) hepatitis. Valaciclovir [valacyclovir] was started, and mesalamine was continued. One year later, she had abdominal pain and worsening diarrhoea. Colonoscopy showed pancolitis. Due to the failure of conventional therapy with mesalamine, vedolizumab was initiated. Six days after the first vedolizumab infusion, she developed vomiting, nausea, fevers and diarrhoea. Serum transaminases were elevated. Elevated HSV IgM 1 and 2 and liver biopsy also confirmed concurrent active chronic hepatitis along with mild portal fibrosis (grade 1, stage 1). RUCAM Score was found to be 8. A diagnosis of DILI secondary to vedolizumab was confirmed.Vedolizumab was discontinued and further clinical and serological improvement was noted with complete recovery in 20 days.

show abstract

Mesalazine/vedolizumab

2021

Reactions Weekly

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

S2721 Did the Drug Do It? A Hepatic Conundrum: Vedolizumab-Related Liver Injury

Cited by 1 publication

References 0 publications

Mesalazine/vedolizumab

Mesalazine/vedolizumab

Contact Info

Product

Resources

About